Cochrane · systematic review · CD011773
Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
Parasramka, S, Talari, G, Rosenfeld, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 2 · 33.3%Moderate 3 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Adults with recurrent GBM
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival | no estimate extracted | 1 study · 35 participants | Low Downgraded: risk of bias, imprecision |
Chemotherapy toxicity | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Comparison
Population: Adults with recurrent HGG
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival median | HR 0.91 [0.74, 1.11] | 1 study · 447 participants | Moderate Downgraded: indirectness |
PFS Median | HR 0.89 [0.73, 1.08] | 1 study · 447 participants | Moderate Downgraded: risk of bias |
QoL EORTC QoL questionnaire C30; at baseline, 12 weeks and 24 weeks | no estimate extracted | 1 study · 415 participants | Low Downgraded: risk of bias, indirectness |
Chemotherapy toxicity During 1st 12 weeks of treatment | no estimate extracted | 1 study · 441 participants | Moderate Downgraded: risk of bias, indirectness |